Related Experiment Videos
[Clinical evaluation of cefteram pivoxil in the pediatric field]
Insights
Cefteram pivoxil (CFTM-PI) is a safe and highly effective oral cephalosporin antibiotic for treating bacterial infections in children. It demonstrated a 98.1% efficacy rate with no severe adverse reactions observed.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Context:
- Antibiotic resistance necessitates novel therapeutic agents.
- Oral cephalosporins are a cornerstone in pediatric infectious disease management.
- Evaluating new antibiotics for pediatric use is crucial for public health.
Purpose:
- To assess the safety and efficacy of Cefteram pivoxil (CFTM-PI) in pediatric patients.
- To determine the clinical effectiveness of CFTM-PI against common pediatric bacterial infections.
- To evaluate the safety profile and tolerability of CFTM-PI in children.
Summary:
- Fifty-three pediatric patients with bacterial infections received CFTM-PI at 8.3-21.8 mg/kg/day.
- High efficacy (98.1%) was observed in treating pharyngitis, otitis media, tracheobronchitis, pneumonia, and skin infections.
- CFTM-PI showed potent activity against *Haemophilus influenzae*, *Streptococcus pyogenes*, and *Streptococcus pneumoniae*, comparable to cephalexin against *Staphylococcus aureus*.
Impact:
- CFTM-PI represents a promising new oral antibiotic option for pediatric bacterial infections.
- The study supports the use of CFTM-PI as a safe and effective treatment in children.
- Findings contribute to the evidence base for pediatric antibiotic therapy and antimicrobial stewardship.
Abstract:
Cefteram pivoxil (CFTM-PI, T-2588), a new oral cephalosporin antibiotic, was evaluated for its safety and efficacy in children. Fifty-three patients with bacterial infections were treated with 8.3 to 21.8 mg/kg/day of CFTM-PI. The drug was very effective (efficacy rate 98.1%) in pharyngitis, otitis media, tracheobronchitis, pneumonia and skin infections. The antibacterial potency was very good against Haemophilus influenzae, Streptococcus pyogenes and Streptococcus pneumoniae, and was comparable with cephalexin against Staphylococcus aureus. No severe adverse reaction was encountered with the CFTM-PI therapy. The data suggest that CFTM-PI is a safe and effective antibiotic when used in children with susceptible bacterial infections.